Insulin Gene in E. coli: Genetic Engineering, Not Gene Therapy
Inserting the human insulin gene into E. coli is genetic engineering (recombinant DNA technology), NOT gene therapy.
Key Distinctions
| Aspect | Genetic Engineering (Insulin Production) | Gene Therapy |
|---|---|---|
| Target | Bacteria (E. coli) or yeast | Human patient's cells |
| Purpose | Manufacture therapeutic protein | Treat/prevent disease in patient |
| Genetic change | Stable plasmid integration in microbe | Modify patient's somatic/germline DNA |
| Product | Recombinant insulin (purified) | Therapeutic effect in vivo |
| Regulation | Biologics manufacturing (FDA/EMA) | Gene therapy trials (strict oversight) |
Historical Context
- 1978: First human insulin produced in E. coli (Genentech)
- 1982: Humulin (recombinant human insulin) FDA-approved—first recombinant drug
- Replaced animal-sourced insulin; identical to human, unlimited supply, fewer reactions
Current Production
- E. coli and S. cerevisiae (yeast) both used commercially
- Fermentation → purification → formulation
- Strict GMP, no viable organisms in final product
This is industrial biotechnology—manufacturing a drug, not treating a patient's genes.
Diabetes - Related Articles
- Exercise and Blood Sugar Control: A Comprehensive Guide
- Gabapentin and Blood Glucose: No Hyperglycemia Risk; Possible Benefit
- Choosing the Right Diabetes Education Program: A Comprehensive Guide
- Hypoglycemia: Understanding Low Blood Sugar and Its Causes
- Home A1c Testing: Convenience, Accuracy & What to Expect
- Diabetes Pathophysiology: Pancreas, Insulin, Glucose Homeostasis & Types
- Type 1 Diabetes Management: Insulin Therapy, Monitoring, and Comprehensive Care
